

Gamzook'aamin aakoziwin

SAUGEEN OJIBWAY NATION - BRUCE POWER PARTNERSHIP

The Production of Medical Isotopes in SON Territory at the Bruce Power Site

The Saugeen Ojibway Nation (SON) and Bruce Power have partnered on the production of the medical isotope Lutetium-177 through the New Isotope Collaboration and Marketing Agreement. SON and Bruce Power will collaborate on marketing these urgently needed medical isotopes in support of the global fight against cancer.

Bruce Power has also partnered with Isogen (Kinectrics and Framatome joint venture) to support the development and implementation of the Isotope Production System (IPS) for the CANDU reactors at the Bruce Power site, and with ITM for the processing and distribution of the medical isotope product(s).



Lutetium-177 (Lu-177) is a medical isotope used in targeted radionuclide therapy to diagnose (image) and treat neuroendocrine tumors, prostate and breast cancer. Lu-177 is used to deliver a radioactive dose to the cancer cells while leaving the body's healthy cells unaffected.

Lu-177, and other medical isotopes, have typically been produced in nuclear reactors and cyclotrons, such as the National Research Universal reactor (NRU). Since the decommissioning of the NRU in 2018, the world is in need of a new supply of reactor medical isotopes to meet the demand from the health sector. The production of Lu-177 at Bruce Power will create a redundant and secure supply of Lu-177, unlike any other production system currently in place.

As partners, the revenue generated by this project will be shared with SON annually and will be used by each of the SON Communities to create new opportunities across SON Territory and for the benefit of SON Community members.

This Partnership is a demonstration of the hard work and determination of SON Leadership and to find a way for SON to participate in the revenue generated in the Territory. The Partnership also demonstrates Bruce Power's recognition that the next 50 years of its operations in SON Territory must be different than the past 50 years. A first step to ensure a new path forward is collaborating with SON on this type of economic opportunity in SON Territory.

SON chose to partner on the production of live-saving medical isotopes not only because the partnership would generate annual revenue for the benefit of the SON Communities, but also because of the significant social and health impact this product will have on any person, family, or Community fighting cancer.

We want SON Community members to be aware of and to be proud of this historic partnership. This partnership and the production of Lu-177 in SON Territory will have significant positive impacts on cancer diagnosis and treatment locally, nationally and around the world!



